Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS

Oct 27 2016

• By Mary Jo Laffler

Related Content

Bristol Still Rules Immuno-Oncology, But For How Long?

Oct 27 2016

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

Oct 10 2016

AstraZeneca’s Durvalumab/Tremelimumab Combo Holds Its Own In NSCLC

Feb 08 2016

AstraZeneca’s Oncology Strategy: It’s All About The End Results

Jun 22 2015

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials ImmunoOncology Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window